Destabilized 3’UTR degradation of ERBB2 in the osimertinib- and trastuzumab-resistant cancer cell lines leads to loss of kinases implicated in breast and lung cancer drug resistance. The gene discussed is ERBB2; the disease is lung carcinoma.